Neurocrine, Neuroscience deal

Neurocrine created Neuroscience Pharma, a Canadian subsidiary to conduct genomics research to identify genes responsible for neurodegenerative diseases. Neuroscience Pharma also will participate in the clinical development of Neurocrine's neurosteroid program to treat memory deficits associated with Alzheimer's disease.

The subsidiary sold 51 percent of the company for C$13 million to a group of investors (see Offerings, B16). Neurocrine established the subsidiary to take advantage of research credits from both the provincial and federal governments and to gain access to Canadian hospitals and patients for trial protocols. ...